Given that apoC1 is implicated in the lipid metabolism (30–32), inflammation (33), and possibly oxidative stress function (34), all of these are known critical components for the pathogenesis involved in GDM, and several studies have identified the two polymorphisms as dyslipidemia- and/or cardiometabolic diseases-linked variants, it is possible that the apoC1 polymorphisms with functional features may influence GDM development and/or associated metabolic traits or phenotypes. This evidence concerns the gene APOC1 and gestational diabetes.